Video
Dr. Figlin on Intermediate Prognosis Patients With mRCC
Author(s):
Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
Robert Figlin, MD, FACP, Professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.
The Memorial Sloan Kettering Cancer Center risk model uses 5 risk factors to divide patients with mRCC into 3 prognostic groups. Researchers associated with this analysis identified 548 intermediate prognosis mRCC patients treated with sunitinib in 6 prospective phase II and III clinical trials.
Figlin says that performance status and time from diagnosis stratify intermediate prognosis patients into better and poorer groups: Progression-free survival and overall survival were superior in patients with 1 versus 2 risk factors and ECOG performance status demonstrated to be an important factor.
